Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue

Wagner, SJ; Skripchenko, Andrey; Robinette, Daniel; Mallory, D. A.; Cincotta, Louis

doi:10.1046/j.1537-2995.1998.38898375511.x

Cited by 61 publications

(58 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, gentian violet may not inactivate other agents that contaminate transfused blood. Other pathogen inactivation systems under evaluation for platelet concentrates and plasma include dimethylene blue and light (23,26), riboflavin and light (24), and an ethylene amine derivative (V.I. Technologies, Inc., Watertown, Mass.)…”

Section: Vol 47 2003 Inactivation Of T Cruzi In Platelets and Plasmentioning

confidence: 99%

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Voorhis

Barrett²,

Eastman³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Trypanosoma cruzi, the protozoan pathogen that causes Chagas' disease, can be found in the blood of infected individuals for their entire life span. This presents a serious challenge in safeguarding blood products. Transmission of T. cruzi from blood products is a frequent occurrence in Latin America, where Chagas' disease is endemic. This study was designed to determine whether T. cruzi could be inactivated in human platelet concentrates and plasma by a photochemical treatment process with long-wavelength UV A light (UVA, 320 to 400 nm) plus the psoralen amotosalen HCl (Cerus Corporation). Units of platelet concentrates (300 ml) and plasma (300 ml) were intentionally contaminated with approximately 10 6 T. cruzi trypomastigotes, the T. cruzi form found in the bloodstream, per ml. The viability of T. cruzi after photochemical inactivation was determined by their ability to replicate in 3T3 fibroblasts. Controls, including treatment with 150 M amotosalen or 3 J/cm 2 UVA alone, did not lead to reduction of the viability of T. cruzi in plasma or platelet concentrates. However, treatment with 150 M amotosalen plus 3 J/cm 2 UVA inactivated T. cruzi to undetectable levels in plasma and platelet concentrates. This represented a >5.4-log reduction of T. cruzi in platelet concentrates and >5.0-log reduction of T. cruzi in plasma. We conclude that the amotosalen plus UVA photochemical inactivation technology is effective in inactivating high levels of protozoan pathogens, such as T. cruzi, in platelet concentrates and plasma, as has been previously shown for numerous viruses and bacteria.

show abstract

Section: Vol 47 2003 Inactivation Of T Cruzi In Platelets and Plasmentioning

confidence: 99%

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Voorhis

Barrett²,

Eastman³

et al. 2003

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…A chemically demethylated derivative (thionin) has been developed for platelet decontamination [82]. Clearly the latter, and the decontamination of erythrocytes [83,84,85,86], presents more of a challenge than simple disinfection of plasma. Recently, studies on the photodynamic inactivation of white blood cells in red blood cell products have been published, too [87].…”

Section: Photodynamic Inactivation Of Bloodmentioning

confidence: 99%

Platelets, photosensitizers, and PDT

Senge

Radomski

2013

Photodiagnosis and Photodynamic Therapy

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has both direct cell and indirect vascular effects. Both are well established and the latter has given rise to specifically target angiogenesis in PDT treatments. While the vascular effects are well understood, further advances in antiangiogenesis require a detailed understanding of PDT effects at the microvasculature level. Although some of the earliest investigations of PDT noted effects on platelet aggregation the importance of their interaction with endothelial cells and the crucial role of various signaling pathways is only now emerging. This review aims to give a general overview of PDT related studies on platelets, vascular effects, and their interaction with endothelial cells to indicate the potential for studies in this area.Abbreviations: ALA --aminolevulinic acid; AMD -age-related macular degeneration; ANET -anti-neovascular therapy; BGF -basic fibroblast growth factor; DHEdihaematoporphyrin ether; EDRF -endothelium-derived relaxing factor; epithelial growth factor -EGF; HIF-1 -hypoxia-inducible factor 1; HpD -haematoporphyrin derivative; IL -interleukin; PAF -platelet activating factor; PDT -photodynamic therapy; PS -photosensitizer; transforming growth factor 1 -TGF-1; TNF -tumor necrosis factor.

show abstract

“…Because the wavelength of light that activates riboflavin is in the visible spectrum, an ordinary source of visible light can be used. A fourth method, which involves dimethylmethylene blue, was pursued by the American Red Cross [45] but is no longer under development.…”

Section: Rbcsmentioning

confidence: 99%

Progress Toward a Pathogen-Free Blood Supply

McCullough

2003

Clinical Infectious Diseases

View full text Add to dashboard Cite

Although the nation's blood supply is safer than ever, a small risk of transfusion-transmitted infection remains. Present strategies to further reduce the risk, such as the donor medical evaluation or laboratory testing, will not likely eliminate this risk. A different approach involves treating donated blood to eliminate its infectivity. A pathogen-inactivated plasma product was available for several years but was recently withdrawn. Several other methods are under development, but all of these prevent nucleic acids from replicating, thus inactivating any contaminating viruses or bacteria. Toxicity, mutagenicity, and safety margins seem to be adequate, and damage to blood proteins or cellular elements is minimal. Clinical trials of pathogen-inactivated platelets have been completed in Europe and in the United States, and phase III clinical trials of pathogen-inactivated red blood cells are underway in the United States. If these encouraging results are sustained, the risk of transfusion-transmitted disease may be nearly eliminated.

show abstract

Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue

Abstract: Dimethylmethylene blue photo-treatment can inactivate several intracellular and extracellular model viruses under conditions which minimally alter RBC properties during 42 days storage at 1-6 degrees C.

Cited by 61 publications

References 21 publications

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Trypanosoma cruziInactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV

Platelets, photosensitizers, and PDT

Progress Toward a Pathogen-Free Blood Supply

Contact Info

Product

Resources

About